Actively Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Led by Deciphera Pharmaceuticals, LLC · Updated on 2026-04-21
60
Participants Needed
4
Research Sites
179 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
CONDITIONS
Official Title
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have confirmed advanced or metastatic renal cell carcinoma, urothelial cancer, or castration-resistant prostate cancer
- Able to take oral medication
- If female of childbearing potential, must have a negative pregnancy test prior to enrollment
- All participants must agree to follow contraception requirements
- Adequate organ function and electrolyte levels
You will not qualify if you...
- Received any prior anticancer therapy or investigational therapy within a specified timeframe before first dose of DCC-2812
- Impaired cardiac function
- Major surgery within 28 days before first dose of study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
2
Vanderbilt- Ingram Cancer Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
3
NEXT Oncology, Austin
Austin, Texas, United States, 78758
Actively Recruiting
4
NEXT Oncology, San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
C
Clinical Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here